健康险解决创新药支付三部曲

Core Viewpoint - The commercial health insurance sector is increasingly positioned as a crucial component of China's multi-tiered medical security system, especially in the context of high prices for innovative drugs and tightening medical insurance payment spaces [1][4]. Group 1: Growth of Commercial Health Insurance - The compensation scale for innovative drugs and medical devices by commercial health insurance has been growing rapidly, with a projected total compensation amount of approximately 14.7 billion yuan by 2025, reflecting a compound annual growth rate of 70% over four consecutive years [3][4]. - The demand for high-quality health insurance is rising due to limited accessibility to high-quality medical services under the current medical insurance system, making commercial health insurance an important supplement [3][4]. Group 2: Challenges Faced by the Industry - The lack of reliable incidence and cost data presents a significant challenge for commercial health insurance in assessing risks associated with innovative drugs, leading to potential profit erosion and losses for insurance companies [5][6][7]. - The industry is working on creating a unified net cost table for commercial medical insurance to improve risk assessment and pricing accuracy, which has historically relied on limited internal data [8][9]. Group 3: Industry Collaboration and Investment - Insurance companies are transitioning from being mere financial payers to becoming collaborative partners within the medical industry, leveraging their capital to support healthcare and elderly care sectors [10][12]. - By 2025, insurance funds are expected to invest over 150 billion yuan in medical-related projects, with direct equity investments in the healthcare sector nearing 30 billion yuan [11][12]. Group 4: Regulatory Environment and Future Directions - The China Insurance Industry Association emphasizes the need to adhere to fundamental insurance principles while expanding product offerings, reflecting a shift towards sustainable commercial practices [14][17]. - The relationship between the National Medical Insurance Administration and the National Financial Regulatory Bureau is characterized by both cooperation and competition, with the former pushing for commercial health insurance to take on more responsibilities [15][16][17].